{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-045897","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.498604+00:00","generated_at":"2026-06-17T01:41:10.259445+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Regeneron Chair P. Roy Vagelos not to stand for re-election; Schleifer and Yancopoulos named Co-Chairs","bullets":["Dr. Vagelos will not stand for re-election at June 9, 2023 Annual Meeting; will serve as Chair until then.","Board plans to elect Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. as Co-Chairs.","Christine A. Poon will become Lead Independent Director effective after the Annual Meeting.","Dr. Vagelos's decision not due to any disagreement with Regeneron."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-045897","json":"https://secwatch.observer/filing/0001104659-23-045897.json","markdown":"https://secwatch.observer/filing/0001104659-23-045897.md","text":"https://secwatch.observer/filing/0001104659-23-045897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/tm2312956d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:41:10.259445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"65fb1eed6b","claim":"P. Roy Vagelos departed as Chair of the Board at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"79c46060f0","claim":"George D. Yancopoulos was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Co-Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"dc4f92e1dc","claim":"Leonard S. Schleifer was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Co-Chair of the Board"}],"fact_type":"executive_change"},{"claim_id":"eb59aae485","claim":"Christine A. Poon was appointed as Lead Independent Director at REGENERON PHARMACEUTICALS, INC..","evidence_excerpt":"and to designate Christine A. Poon as the Lead Independent Director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"designated"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}